prikaz prve stranice dokumenta Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
  Download
PDF 758.17 KB
Scientific paper - Original scientific paper
Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
Revista médica de Chile, 147 (2019), 5; 557-567. https://doi.org/10.4067/S0034-98872019000500557
Kustić, Domagoj; Lovasić, Franjo; Belac-Lovasić, Ingrid; Avirović, Manuela; Ružić, Alen; Petretić-Majnarić, Silvana

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Kustić, D., Lovasić, F., Belac Lovasić, I., Avirović, M., Ružić, A. & Petretić Majnarić, S. (2019). Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma. Revista médica de Chile, 147. (5), 557-567. doi: 10.4067/S0034-98872019000500557

Kustić, Domagoj, et al. "Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma." Revista médica de Chile, vol. 147, no. 5, 2019, pp. 557-567. https://doi.org/10.4067/S0034-98872019000500557

Kustić, Domagoj, Franjo Lovasić, Ingrid Belac Lovasić, Manuela Avirović, Alen Ružić and Silvana Petretić Majnarić. "Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma." Revista médica de Chile 147, no. 5 (2019): 557-567. https://doi.org/10.4067/S0034-98872019000500557

Kustić, D., et al. (2019) 'Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma', Revista médica de Chile, 147(5), pp. 557-567. doi: 10.4067/S0034-98872019000500557

Kustić D, Lovasić F, Belac Lovasić I, Avirović M, Ružić A, Petretić Majnarić S. Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma. Revista médica de Chile [Internet]. 2019 May [cited 2024 May 11];147(5):557-567. doi: 10.4067/S0034-98872019000500557

D. Kustić, F. Lovasić, I. Belac Lovasić, M. Avirović, A. Ružić and S. Petretić Majnarić, "Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma", Revista médica de Chile, vol. 147, no. 5, pp. 557-567, May 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:918657. [Accessed: 11 May 2024]

Metadata
Title (english)Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
AuthorDomagoj Kustić
AuthorFranjo Lovasić
AuthorIngrid Belac-Lovasić
AuthorManuela Avirović
AuthorAlen Ružić
AuthorSilvana Petretić-Majnarić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Surgery)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Nuclear Medicine)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of General Pathology and Pathological Anatomy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
BACKGROUND: Breast cancer (BC) is the most common malignancy in women. AIM: To assess the impact of HER2 status on axillary lymph node (ALN) involvement in patients with invasive ductal carcinoma of no special type (IDC-NST) both at diagnosis and during the 4-year postoperative period. PATIENTS AND METHODS: We retrospectively included 375 women with an early clinical stage of non-luminal IDC-NST who between 2007 and 2013 underwent breast surgery at a clinical hospital. They were divided into phenotype-based groups: HR+HER2-, HR+HER2+, HR-HER2+ and HR-HER2-. Only patients with sentinel lymph node (SLN) macrometastases underwent ALN dissection. If > 3 ALNs were positive, radiotherapy was delivered. All patients were treated with chemotherapy, HER2+ BC patients received trastuzumab, and hormone receptor (HR)-positive BC patients received hormonal therapy. RESULTS: Larger tumor size, higher grade, HR+, HER2+ status, and lymphovascular invasion (LVI) were predictive for ALN metastases at diagnosis. The poorest overall, disease-free, and distant recurrence-free survival (OS, DFS, DRFS) were found in the HR-HER2- group, while the poorest locoregional recurrence-free survival (LRFS) was observed in HR-HER2+ and HR-HER2- groups. HER2 status was not predictor of survival. CONCLUSIONS: HER2+ status was predictive for ALN involvement at diagnosis but had no effect on 4-year LRFS in these patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleRevista médica de Chile
Numberingvol. 147, no. 5, pp. 557-567
p-ISSN0034-9887
DOIhttps://doi.org/10.4067/S0034-98872019000500557
URN:NBNurn:nbn:hr:184:918657
Publication2019-05
Document URLhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000500557&lng=en&nrm=iso&tlng=en
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2020-03-30 08:06:34